Rituximab usage and dosage

Rituximab (Rituximab) is a genetically engineered chimeric mouse/human monoclonal antibody. Rituximab is used to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris and rheumatoid arthritis.

Rituximab is administered as an intravenous infusion only. Do not give by intravenous push or bolus injection. Rituximab should only be used by a physician with appropriate medical support to control serious infusion-related reactions, which may be fatal if serious adverse reactions occur. For patients with relapsed or refractory low-grade or follicular antigenCD20positiveB cell non-Hodgkin lymphoma, the recommended dose is37 5mg/m22once a week for 4 weeks or 8 weeks, if disease subsequently progresses after response to prior rituximab therapy, then an additional course of 375 mg/m given 2 once weekly for 4 weeks. For patients with relapsed or refractory indolent NHL or relapsed or refractory mantle cell lymphoma, give 375 on day 1 of the 28 cycle mg/m2 of bendamustine hydrochloride for a total of 4-6 cycles (day 2 and day 3 intravenously 90 mg/m2). Administer an additional dose of rituximab one week before the first cycle of bendamustine-rituximab and repeat the dose 28 days after the last cycle of bendamustine-rituximab. For patients with previously untreated follicular, antigenCD20positiveB cell non-Hodgkin lymphoma, the recommended dose is 375 mg/m2 on day 1 of each chemotherapy cycle, up to8agent. For patients with previously untreated advanced indolent non-Hodgkin lymphoma or previously untreated advanced mantle cell lymphoma, give 375 on day 1 of the 28 cycle. mg/m2 of bendamustine hydrochloride (90 mg/m2 intravenously on days 1 and 2 days) for a maximum of 8 cycles. For patients with non-progressive low-grade antigenCD20positiveB cell non-Hodgkin lymphoma who received 6-8cyclesCVPFirst-line treatment of non-progressive (including stable disease) patients with chemotherapy,375 mg/m2 once a week for 4 weeks; repeat every 6 months for a maximum of 16 doses. For patients with previously untreated diffuse largeB cell, antigenCD20-positive, non-Hodgkin lymphoma, Day 1 of each chemotherapy cycle375 mg/m2, up to 8 doses. For patients with chronic lymphocytic leukemia, cycle 1:cycle 0Day375mg/m2 (FCThe day before chemotherapy), No. 2-6Cycle:The 1day of each FCchemotherapy cycle span>500mg/m2; repeat every 28 days, up to 5 doses. For patients with rheumatoid arthritis, administer 1 on days 1 and 15 days apart 2 g (total 2 doses), the treatment course can be repeated every 24 weeks or according to clinical response, but the interval between two courses should not be earlier than every 16 weeks. If you want to get more high-quality information, you can contact YaoDe,Yaidewill do its best to learn more about high-quality overseas drugs for you.